Minkyung Song

Assistant Professor

Sungkyunkwan University
Country flagSouth Korea
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.

Year:

2025

Iron accumulation in tumors contributes to disease progression and chemoresistance. Although targeting this process can influence various hallmarks of cancer, the immunomodulatory effects of iron chelation in the tumor microenvironment are unknown. Here, we report that treatment with deferiprone, an FDA-approved iron chelator, unleashes innate immune responses that restrain ovarian cancer. Deferiprone reprogrammed ovarian cancer cells toward an immunostimulatory state characterized by the production of type-I IFN and overexpression of molecules that activate NK cells. Mechanistically, these effects were driven by innate sensing of mitochondrial DNA in the cytosol and concomitant activation of nuclear DNA damage responses triggered upon iron chelation. Deferiprone synergized with chemotherapy and prolonged the survival of mice with ovarian cancer by bolstering type-I IFN responses that drove NK cell-dependent control of metastatic disease. Hence, iron chelation may represent an alternative immunotherapeutic strategy for malignancies that are refractory to current T-cell–centric modalities. Significance: This study uncovers that targeting dysregulated iron accumulation in ovarian tumors represents a major therapeutic opportunity. Iron chelation therapy using an FDA-approved agent causes immunogenic stress responses in ovarian cancer cells that delay metastatic disease progression and enhance the effects of first-line chemotherapy. See related commentary by Bell and Zou, p. 1771

Year:

2024

Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.

Year:

2024

Collaborators (12)

Dmitriy Zamarin

Professor and Section Head, Gynecologic Medical Oncology

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Suzanne Cloonan

Associate Professor in Respiratory Biochemistry

Weill Cornell Medicine

UNITED STATES
View details

Juan Cubillos-Ruiz

Professor of Microbiology and Immunology

Weill Cornell Medicine

UNITED STATES
View details

Diana K. Morales

Associate Professor of Microbiology

Weill Cornell Medical College

UNITED STATES
View details

Deepika Awasthi

Weill Cornell Medicine

UNITED STATES
View details

Melissa Frey

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Anna Vähärautio

University of Helsinki

FINLAND
View details

Matias Marin Falco

University of Helsinki

FINLAND
View details

Evelyn Cantillo

Weill Cornell Medicine

UNITED STATES
View details

Lorenzo Galluzzi

-

UNITED STATES
View details

Hui-Hsuan Kuo

Northwestern University

UNITED STATES
View details

Christopher Mason

Professor

Weill Cornell Medical College

UNITED STATES
View details